Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Advanced Liver Cancer Market from 2024 to 2025?
The market size for advanced liver cancer has seen significant growth in the recent past. The market is predicted to expand from a value of $1.89 billion in 2024 to $2.17 billion in 2025, displaying a compound annual growth rate (CAGR) of 15.2%. Factors contributing to the growth during the historical period include heightened awareness about liver cancer, an increasing number of patients, heightened need for targeted treatments, improvements in healthcare infrastructure, and an increased interest in minimally invasive procedures.
What Is the Projected Market Size of the Advanced Liver Cancer Market?
Anticipations are high for a swift expansion in the advanced liver cancer market in the upcoming years. The market is projected to surge to $3.78 billion by 2029, boasting a 14.8% compound annual growth rate (CAGR). This surge in the forecast period can be attributed to factors such as the rising incidence of liver cancer, escalated health care expenditure, the escalation in the prevalence of genetic conditions, increased application of precision medicine, and a surge in the adoption of screening and diagnostic tests. Major tendencies over the forecast period include the incorporation of artificial intelligence in therapy, the creation of groundbreaking drugs and treatments, extensive research and development events, advancements in targeted therapeutics, and a rising demand for personalized medicine.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20706&type=smp
Who are the Major Competitors in the Advanced Liver Cancer Market Outlook?
Major companies operating in the advanced liver cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Stryker Corporation, Agilent Technologies Inc., Eisai Co. Ltd., Jiangsu Hengrui Pharmaceutical Co. Ltd, Exelixis Inc., Sirtex Medical Limited, Eureka Therapeutics, Abbisko Therapeutics Co. Ltd., Binhui Biopharmaceutical Co. Ltd., Tempest Therapeutics Inc., Auransa Inc., Mina Alpha Limited, Jennerex Inc.
What Is Fueling Growth in the Advanced Liver Cancer Market?
The advanced liver cancer market’s expansion is likely to be fueled by the increasing incidences of long-standing hepatitis infections. These infections, which are persistent viruses present in the body for over six months, can lead to liver harm, cirrhosis, or liver cancer. Factors such as insufficient screening and vaccination, coupled with delayed treatment access, accentuate the uptick in enduring hepatitis cases. Both Hepatitis B (HBV) and Hepatitis C (HCV) chronic infections are singled out as substantial drivers of liver cirrhosis and hepatocellular carcinoma (HCC), which is the most frequent liver cancer type. These persistent viral infections may escalate into liver inflammation, damage, and potentially cancer over time. With the persistence of these infections, an increased number of individuals may be susceptible to advanced liver cancer. For example, the World Health Organization, a Switzerland-based intergovernmental organization, highlighted in April 2024 that chronic hepatitis B was estimated to have impacted 254 million people globally in 2022, with an annual reporting of 1.2 million new cases. Consequently, the escalating occurrences of long-lasting hepatitis infections are stimulating the expansion of the advanced liver cancer market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=20706&type=smp
Which Advanced Liver Cancer Market Segments Are Growing the Fastest?
The advanced liver cancer market covered in this report is segmented –
1) By Test Type: Imaging Test, Biopsy, Genomic Test, Other Test Types
2) By Technology: Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluoroimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, Other Technologies
3) By Distribution Channel: Direct Tenders, Retail Sales, Other Distribution Channel
4) By Application: Screening, Diagnostic And Predictive, Prognostic, Research
5) By End-User: Hospitals, Cancer Research Centers, Academic Institutes, Diagnostic Centers, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Imaging Test: Ultrasound, CT (Computed Tomography) Scan, MRI (Magnetic Resonance Imaging), PET (Positron Emission Tomography) Scan
2) By Biopsy: Needle Biopsy, Laparoscopic Biopsy, Surgical Biopsy
3) By Genomic Test: Next-Generation Sequencing (NGS), PCR (Polymerase Chain Reaction) Testing, Genetic Mutation Profiling
4) By Other Test Types: Serum Biomarker Testing, Liver Function Tests, Alpha-Fetoprotein (AFP) Test, Elastography Tests
Which Industry Trends Are Shaping the Future of the Advanced Liver Cancer Market?
Firms operating in the advanced liver cancer market, such as AstraZeneca, are focusing on the development of innovative treatments for better patient outcomes. These treatments include human monoclonal antibodies, which are lab-engineered molecules that can mimic the immune system’s role in fighting cancer cells and other harmful pathogens. These molecules specifically target certain antigens present on the surface of these dangerous entities to prompt an immune reaction. For example, in October 2022, American pharmaceutical giant AstraZeneca announced that its drug Imjudo (tremelimumab), in combination with Imfinzi (durvalumab), received approval from the US Food and Drug Administration (FDA) for the treatment of unresectable hepatocellular carcinoma (HCC) in adults. HCC is the most prevalent kind of liver cancer. This combo therapy’s approval was based on the HIMALAYA Phase III trial outcomes, indicating that the risk of death is lowered by 22% compared to sorafenib and that around 31% of patients survived after three years compared to 20% of patients on sorafenib. This treatment protocol, known as STRIDE, involves a single dosage of Imjudo, followed by routine four-weekly doses of Imfinzi, providing a new treatment alternative for patients with limited options.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/advanced-liver-cancer–global-market-report
Which Countries Are Leading the Advanced Liver Cancer Market?
North America was the largest region in the advanced liver cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced liver cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20706
This Report Delivers Insight On:
1. How big is the advanced liver cancer market, and how is it changing globally?
2. Who are the major companies in the advanced liver cancer market, and how are they performing?
3. What are the key opportunities and risks in the advanced liver cancer market right now?
4. Which products or customer segments are growing the most in the advanced liver cancer market?
5. What factors are helping or slowing down the growth of the advanced liver cancer market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
